Category - Feature

Feature

IntelGenx has multi-faceted BD approach for its oral films

By Len Zehr With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with...

May 16, 2017

Feature

3DS’ genomic imaging for precision medicine

By Len Zehr As CEO of 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) since last September, Jason Flowerday is putting the diagnostic company on people’s radar. Unlike most diagnostic companies, 3DS’ proprietary imaging...

May 2, 2017

Feature

Titan’s next ProNeura-based implant dovetails with PD awareness month

By Len Zehr After receiving FDA approval last year for its Probuphine implant as a maintenance treatment for opioid addiction, Titan Pharmaceuticals (NASDAQ:TTNP) is employing its ProNeura drug delivery technology to...

April 25, 2017

Feature

Checkpoint targeting registration studies by end of 2018

Checkpoint Therapeutics (OTCQX:CKPT) is taking an “aggressive path forward” with its clinical programs and expects to be in registration studies at the end of 2018 with its lead targeted anti-cancer agent, CK-101, and...

April 18, 2017

Feature

Lion Biotechnologies spearheading TILs in solid tumors

By Len Zehr Lion Biotechnologies (NASDAQ:LBIO) is establishing a leading position in immuno-oncology through its tumor-infiltrating lymphocyte (TIL) technology to deliver personalized oncology therapies to patients with...

April 11, 2017

Feature

Ortho RTi developing biologic scaffold for soft issue injuries

By Len Zehr Ortho Regenerative Technologies is developing a “sticky scaffold” biologic that has the potential to be best in class to repair symptomatic lesions in shoulder tendons, knee meniscus and articular cartilage...

April 4, 2017

Feature

Profound Medical’s TULSA-PRO pilot OUS launch: paving the way for global growth

By Len Zehr After nearly a decade of R&D, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is now conducting a pilot launch of its TULSA-PRO medical device to ablate tissue in localized prostate cancer within key European...

March 28, 2017

Feature

Vyome completing enrollment in acne POC trial

By Len Zehr Closely-held Vyome Biosciences expects to enroll the final patient next month in a proof-of-concept clinical trial of its lead molecule for drug-resistant acne, VB 1953. “Our product has the potential to be...

March 21, 2017

Feature

Histogenics to complete Phase 3 enrollment in Q2

By Len Zehr Histogenics (NASDAQ:HSGX) expects to complete enrollment by the end of the second quarter this year in a Phase 3 clinical trial of its NeoCart biologic cell therapy and tissue engineering solution for knee...

March 14, 2017

Feature

Arch moving to regulatory stage this year

By Len Zehr Arch Therapeutics (OTCQB:ARTH) has multiple regulatory filings planned in the U.S. and Europe this year for its AC5 Topical Hemostatic Device as the biopharma company shifts to regulatory-stage footing ahead...

March 7, 2017

Category - Feature

IntelGenx has multi-faceted BD approach for its oral films

3DS’ genomic imaging for precision medicine

Titan’s next ProNeura-based implant dovetails with PD awareness month

Checkpoint targeting registration studies by end of 2018

Lion Biotechnologies spearheading TILs in solid tumors

Ortho RTi developing biologic scaffold for soft issue injuries

Profound Medical’s TULSA-PRO pilot OUS launch: paving the way for global growth

Vyome completing enrollment in acne POC trial

Histogenics to complete Phase 3 enrollment in Q2

Arch moving to regulatory stage this year

General

More